In the phase III IMpower150 trials involving untreated patients with advanced non-squamous NSCLC, the combination of bevacizumab and platinum-based chemotherapy and atezolizumab improved PFS compared with chemotherapy and bevacizumab, regardless of the PD-L1 expression status (54). This evidence concerns the gene CD274 and non-small cell lung carcinoma.